Tumour escape from the immune response

By Pawelec G.  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 10, 2004-10 ,pp. : 843-843

Springer Publishing Company

Access to resources Recommend Favorite

Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses

By              

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 529-534

Spandidos Publications

Access to resources Recommend Favorite

The contribution of dendritic cells to immune responses against urological cancers - T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

By Troy A.   Davidson P.   Atkinson C.   Hart D.  

Urologic Oncology: Seminars and Original Investigations, Vol. 4, Iss. 1, 1998-01 ,pp. : 17-23

Elsevier

Access to resources Recommend Favorite

Editorial comment on 'Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma' by Hogg and colleagues

By van den Brekel M.W.M.   Balm A.J.M.  

European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. : 1561-1563

Elsevier

Access to resources Recommend Favorite

Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma

By Hogg R.P.   Honorio S.   Martinez A.   Agathanggelou A.   Dallol A.   Fullwood P.   Weichselbaum R.   Kuo M.J.   Maher E.R.   Latif F.  

European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. : 1585-1592

Elsevier

Access to resources Recommend Favorite